Baillie Gifford & Co
CELL

Baillie Gifford & Co’s PhenomeX Inc. Common Stock CELL Stock Holding History

Baillie Gifford & Co’s Portfolio CELL Stock Details CELL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-603,544
Closed -$296K – 301
2023
Q2 		$296K Sell
603,544
-743,338
-55% -$608K ﹤0.01% 283
2023
Q1 		$1.56M Sell
1,346,882
-419
-0% -$766 ﹤0.01% 259
2022
Q4 		$3.61M Sell
1,347,301
-2,370,899
-64% -$6.25M ﹤0.01% 251
2022
Q3 		$10.6M Buy
3,718,200
+39,216
+1% +$167K 0.01% 209
2022
Q2 		$18.3M Buy
3,678,984
+139,078
+4% +$729K 0.02% 195
2022
Q1 		$25.2M Buy
3,539,906
+211,420
+6% +$1.75M 0.02% 199
2021
Q4 		$60.5M Buy
3,328,486
+392,452
+13% +$8.47M 0.03% 172
2021
Q3 		$57.4M Buy
2,936,034
+703,456
+32% +$26.8M 0.03% 178
2021
Q2 		$100M Buy
2,232,578
+1,113,235
+99% +$51.6M 0.05% 153
2021
Q1 		$56.2M Buy
1,119,343
+342,283
+44% +$23.3M 0.03% 175
2020
Q4 		$69.5M Buy
777,060
+171,717
+28% +$14.4M 0.04% 148
2020
Q3 		$46.2M Buy
+605,343
New +$38.4M 0.03% 156

Other funds holding CELL

BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
TAM
Terrapin Asset Management Miami, Florida $87.8M AUM 16.84% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $449M AUM 51.52% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Baillie Gifford & Co's CELL Position: Q3 2023 in Review

Baillie Gifford & Co sold out of PhenomeX Inc. Common Stock (CELL) in Q3 2023, closing a stake of 603,544 shares — an estimated $296K sold.

Baillie Gifford & Co first reported a position in CELL in Q3 2020 and held it in 12 quarters. The position peaked at $100M in Q2 2021. 57 funds tracked by Wall St. Rank hold CELL as of Q3 2023.

  • Baillie Gifford & Co reported no remaining PhenomeX Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 603,544 PhenomeX Inc. Common Stock shares in Q3 2023, an estimated $296K.
  • Baillie Gifford & Co first reported a position in PhenomeX Inc. Common Stock in Q3 2020 and held it in 12 quarters.
  • Baillie Gifford & Co's PhenomeX Inc. Common Stock position peaked at $100M in Q2 2021.
  • 57 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q3 2023.

Based on Baillie Gifford & Co's 13F filing for Q3 2023, filed 13 Nov 2023.